In ALS, the elevation of NF-l in cerebrospinal fluid levels exceeds that observed in most other neurological diseases, making it useful for the discrimination from mimic conditions and potentially worthy of consideration for introduction as a biomarker for ALS progression [40]. This evidence concerns the gene NEFL and nervous system disorder.